Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination

Inflammopharmacology · Published 2026-07-28 · DOI 10.1007/s10787-026-02350-y

Free full text

Authors (3)

Ghada A. Badawi, Rehab M. El-Sayed, Mohamed N. Fawzy

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Badawi, G., El-Sayed, R., Fawzy, M. (2026). Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination. Inflammopharmacology. https://doi.org/10.1007/s10787-026-02350-y

Related articles

• Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment? · Immune Network · 2025 · Cites or is cited by this article
• A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis · Acta Neuropathologica · 2026 · Cites or is cited by this article
• Immune dysregulation in fibromyalgia: Targeting the NLRP3 inflammasome-ferroptosis axis as a novel therapeutic strategy for chronic pain · Clinical Immunology · 2026 · Cites or is cited by this article
• Treatment Effects on Chronic Active Lesions in Multiple Sclerosis: Current Evidence and Future Perspectives · Neurology and Therapy · 2026 · Cites or is cited by this article
• The impact of ketogenic diet on the onset and progression of multiple sclerosis · European Journal of Microbiology and Immunology · 2023 · Cites or is cited by this article
• Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis · Drugs · 2026 · Cites or is cited by this article
• The dual role of the COX-2/PGE2 Axis in multiple sclerosis: From pathogenesis to pharmacological inhibition · Clinical Immunology · 2025 · Cites or is cited by this article
• Treg Susceptibility to Cladribine-Induced Depletion Correlates With Therapy Response in Patients With Multiple Sclerosis · Neurology: Neuroimmunology & Neuroinflammation · 2025 · Cites or is cited by this article
• Targeting the PI3K/AKT/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions · SAUDI PHARMACEUTICAL JOURNAL · 2026 · Cites or is cited by this article
• Targeting the microbiome-NLRP3-ferroptosis axis in multiple sclerosis: Neuropharmacological implications for microglial dysfunction and demyelination · NEUROPHARMACOLOGY · 2026 · Cites or is cited by this article